DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 3,200 shares of the company’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Andrew K. Balo also recently made the following trade(s):

  • On Monday, June 12th, Andrew K. Balo sold 3,200 shares of DexCom stock. The stock was sold at an average price of $69.06, for a total value of $220,992.00.
  • On Wednesday, May 10th, Andrew K. Balo sold 3,200 shares of DexCom stock. The stock was sold at an average price of $71.93, for a total value of $230,176.00.

DexCom, Inc. (NASDAQ DXCM) opened at 71.72 on Monday. The stock has a 50 day moving average price of $71.68 and a 200 day moving average price of $74.65. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38. The company’s market capitalization is $6.19 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The business had revenue of $142.30 million for the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. Analysts anticipate that DexCom, Inc. will post ($0.71) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) EVP Sells $228,960.00 in Stock” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/dexcom-inc-dxcm-evp-sells-228960-00-in-stock/1445150.html.

Several analysts have recently issued reports on DXCM shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of DexCom in a research note on Wednesday, March 22nd. Canaccord Genuity restated a “buy” rating and set a $90.00 target price on shares of DexCom in a research note on Wednesday, June 7th. Piper Jaffray Companies restated an “overweight” rating and set a $78.00 target price on shares of DexCom in a research note on Monday, May 22nd. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $89.47.

A number of hedge funds have recently modified their holdings of DXCM. Eqis Capital Management Inc. boosted its stake in shares of DexCom by 35.1% in the second quarter. Eqis Capital Management Inc. now owns 9,917 shares of the medical device company’s stock worth $725,000 after buying an additional 2,578 shares during the period. Mn Services Vermogensbeheer B.V. boosted its position in DexCom by 508.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 13,722 shares of the medical device company’s stock worth $1,004,000 after buying an additional 11,468 shares during the period. Chevy Chase Trust Holdings Inc. boosted its position in DexCom by 10.4% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 46,889 shares of the medical device company’s stock worth $3,430,000 after buying an additional 4,399 shares during the period. Bank of Montreal Can boosted its position in DexCom by 69.2% in the second quarter. Bank of Montreal Can now owns 31,403 shares of the medical device company’s stock worth $2,296,000 after buying an additional 12,847 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in DexCom during the second quarter worth about $322,000.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.